Daniel El Fassi

1.7k total citations
36 papers, 725 citations indexed

About

Daniel El Fassi is a scholar working on Genetics, Immunology and Rheumatology. According to data from OpenAlex, Daniel El Fassi has authored 36 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Immunology and 11 papers in Rheumatology. Recurrent topics in Daniel El Fassi's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Eosinophilic Disorders and Syndromes (8 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Daniel El Fassi is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Eosinophilic Disorders and Syndromes (8 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Daniel El Fassi collaborates with scholars based in Denmark, United States and Sweden. Daniel El Fassi's co-authors include Claus Henrik Nielsen, Hans Carl Hasselbalch, László Hegedüs, Laszlo Hegedüs, Steen Joop Bonnema, Jacqueline A. Gilbert, J. Paul Banga, Carolyn J. Padoa, Christen Lykkegaard Andersen and Lasse Kjær and has published in prestigious journals such as Blood, The Journal of Clinical Endocrinology & Metabolism and Analytical Biochemistry.

In The Last Decade

Daniel El Fassi

36 papers receiving 714 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel El Fassi Denmark	14	257	235	180	173	131	36	725
Soma Jyonouchi United States	18	187 0.7×	229 1.0×	107 0.6×	46 0.3×	185 1.4×	41	969
C. Bigorgne France	13	439 1.7×	502 2.1×	292 1.6×	52 0.3×	88 0.7×	33	1.2k
T R Dykman United States	9	88 0.3×	113 0.5×	59 0.3×	230 1.3×	189 1.4×	10	898
G T Swana United Kingdom	14	70 0.3×	118 0.5×	139 0.8×	60 0.3×	70 0.5×	17	888
Dragomir Marisavljević Serbia	16	25 0.1×	117 0.5×	131 0.7×	307 1.8×	119 0.9×	69	650
Paola Orsini Italy	18	335 1.3×	66 0.3×	121 0.7×	182 1.1×	236 1.8×	38	803
Tony Frisk Sweden	13	296 1.2×	106 0.5×	64 0.4×	97 0.6×	349 2.7×	23	857
Daniel Couriel United States	10	27 0.1×	131 0.6×	90 0.5×	332 1.9×	50 0.4×	20	663
Cleonice Bueno Brazil	15	32 0.1×	94 0.4×	36 0.2×	67 0.4×	100 0.8×	40	630
G Lambertenghi Deliliers Italy	13	20 0.1×	198 0.8×	298 1.7×	340 2.0×	164 1.3×	21	865

Countries citing papers authored by Daniel El Fassi

Since Specialization

Citations

This map shows the geographic impact of Daniel El Fassi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel El Fassi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel El Fassi more than expected).

Fields of papers citing papers by Daniel El Fassi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel El Fassi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel El Fassi. The network helps show where Daniel El Fassi may publish in the future.

Co-authorship network of co-authors of Daniel El Fassi

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel El Fassi. A scholar is included among the top collaborators of Daniel El Fassi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel El Fassi. Daniel El Fassi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trier, Nicole Hartwig, Per Brinch Hansen, Morten Orebo Holmström, et al.. (2023). Antibodies to calnexin and mutated calreticulin are common in human sera. Current Research in Translational Medicine. 71(2). 103380–103380. 2 indexed citations

Stensvold, Christen Rune, Signe Ledou Nielsen, Holger Jon Møller, et al.. (2023). Neoehrlichia mikurensis—An emerging opportunistic tick‐borne infection in immunosuppressed patients. Journal of Internal Medicine. 293(6). 782–790. 10 indexed citations

Christoffersen, Mette, Hanne Lindegaard, Jesper Rømhild Davidsen, et al.. (2023). The multidisciplinary approach to eosinophilia. Frontiers in Oncology. 13. 1193730–1193730. 13 indexed citations

Holmström, Morten Orebo, Evelina Martinenaite, Daniel El Fassi, et al.. (2023). An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. Frontiers in Immunology. 14. 1117466–1117466. 8 indexed citations

Saini, Sunil Kumar, Anne-Mette Bjerregaard, Ashwin Unnikrishnan, et al.. (2022). Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies. Leukemia. 36(11). 2734–2738. 4 indexed citations

Simões, Ana Micaela Carnaz, Morten Orebo Holmström, Carlos Zamora, et al.. (2022). Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. Frontiers in Immunology. 13. 866610–866610. 2 indexed citations

Omar, Massar, Andreas Glenthøj, Daniel El Fassi, et al.. (2022). Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial. European Journal of Heart Failure. 25(2). 226–234. 48 indexed citations

Dufva, Inge Høgh, Anne Ortved Gang, Lone Schejbel, et al.. (2021). Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial. Cancer Immunology Immunotherapy. 71(2). 433–444. 10 indexed citations

Grønbæk, Kirsten, et al.. (2021). A user's guide to multicolor flow cytometry panels for comprehensive immune profiling. Analytical Biochemistry. 627. 114210–114210. 18 indexed citations

10.

Schejbel, Lone, Guy Wayne Novotny, Daniel El Fassi, et al.. (2021). Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis. Molecular Diagnosis & Therapy. 25(2). 251–266. 6 indexed citations

11.

Straaten, Stephanie van, Arjen M. Punt, Jesper Petersen, et al.. (2021). A Comprehensive Analysis of the Erythropoietin-erythroferrone-hepcidin Pathway in Hereditary Hemolytic Anemias. HemaSphere. 5(9). e627–e627. 8 indexed citations

12.

Helweg‐Larsen, Jannik, Søren Lykke Petersen, Peter Kampmann, et al.. (2020). Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis. Journal of Fungi. 6(4). 268–268. 8 indexed citations

13.

Eldrup, Ebbe, Simone Theilade, John E. Nielsen, et al.. (2020). Hypercalcemia After Cosmetic Oil Injections: Unraveling Etiology, Pathogenesis, and Severity. Journal of Bone and Mineral Research. 36(2). 322–333. 8 indexed citations

14.

Dufva, Inge Høgh, Anne Ortved Gang, Lone Schejbel, et al.. (2020). Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial. Blood. 136(Supplement 1). 23–24. 4 indexed citations

15.

Sørensen, Anders Lindholm, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.. (2019). Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica. 105(9). 2262–2272. 77 indexed citations

16.

Mikkelsen, Stine Ulrik, Lasse Kjær, Mads Emil Bjørn, et al.. (2018). Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine. 7(8). 3571–3581. 35 indexed citations

17.

Fassi, Daniel El, et al.. (2009). Detrimental and protective roles of B cells: Lessons learned from administration of rituximab to patients with Graves disease. European Journal of Immunology. 1 indexed citations

18.

Fassi, Daniel El, J. Paul Banga, Jacqueline A. Gilbert, et al.. (2008). Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clinical Immunology. 130(3). 252–258. 75 indexed citations

19.

Nielsen, Claus Henrik, Daniel El Fassi, Hans Carl Hasselbalch, Klaus Bendtzen, & László Hegedüs. (2007). B-cell depletion with rituximab in the treatment of autoimmune diseases. Expert Opinion on Biological Therapy. 7(7). 1061–1078. 38 indexed citations

20.

Fassi, Daniel El, Claus Henrik Nielsen, Hans Carl Hasselbalch, & László Hegedüs. (2006). The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. European Journal of Endocrinology. 154(5). 623–632. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact